Advertisement

European Journal of Dermatology

, Volume 28, Issue 3, pp 332–337 | Cite as

PSOdisk is a reliable, intuitive instrument for the evaluation of psychological distress, which strongly correlates with DLQI: a preliminary study

  • Emanuele Cozzani
  • Dennis Linder
  • Martina Burlando
  • Fabio Gallo
  • Francesca Sampogna
  • Marco Bruzzone
  • Carlotta Tacchino
  • Francesco Drago
  • Aurora Parodi
Clinical Report
  • 6 Downloads

Abstract

Background

PSOdisk is a 10-item visual instrument, aimed at assessing the burden of disease in patients with psoriasis.

Objectives

To compare PSOdisk with a scientifically validated questionnaire, the Dermatology Life Quality Index (DLQI), and asses both tools in relation to Psoriasis Severity Index (PASI) and patient acceptance.

Materials & Methods

Fifty patients with cutaneous psoriasis and/or arthritic psoriasis were recruited. Correlation analysis between PSOdisk and DLQI was performed using Pearson’s product-moment correlation coefficient. A multivariate linear regression was carried out to investigate the effect of PASI on PSOdisk and DLQI scores. In addition, we evaluated completion times as well as patient satisfaction for both PSOdisk and DLQI.

Results

PSOdisk and DLQI mean scores were 22.04 ± 20.56 and 3.35 ± 4.52, respectively. The mean value for PASI was 5.98 ± 5.89 and for age was 55.88 ± 14.09 years. The mean value of Cronbach’s coefficient alpha was 0.88 for PSOdisk and 0.90 for DLQI, suggesting good reliability. A significant correlation was found between PSOdisk and PASI, and a statistically significant correlation between DLQI and PASI. Multivariate linear regression analysis demonstrated a statistically significant effect of PASI on both the DLQI score and PSOdisk score.

Conclusions

PSOdisk demonstrates good correlation with DLQI and PASI, good patient satisfaction, and requires a short completion time.

Key words

daily clinical practice DLQI intuitive instrument PSOdisk psoriasis psychological distress 

References

  1. 1.
    Lima XT, Minnillo R, Spencer JM, Kimball AB. Psoriasis prevalence among the 2009 AAD National Melanoma/Skin Cancer Screening Program participants. J Eur Acad Dermatol Venerol 2013; 6: 680–5.CrossRefGoogle Scholar
  2. 2.
    Cozzani E, Borrini V, Pennella A, et al. The quality of life in Italian psoriatic patients treated with biological drugs. G Ital Dermatol Venereol 2010; 145: 709–12.PubMedGoogle Scholar
  3. 3.
    Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr., Reboussin DM. Psoriasis cause as much disability as other major medical diseases. JAAD 1999; 41: 401–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Devrimci–Ozguven H, Kundakci TN, Kumbasar H, Boyvat A. The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients. J Eur Acad Dermatol Venereol 2000; 14: 267–71.CrossRefPubMedGoogle Scholar
  5. 5.
    Gupta MA, Gupta AK. Psoriasis and sex:a study of moderately to severely affected patients. Int J Dermatol 1997; 36: 259–62.CrossRefPubMedGoogle Scholar
  6. 6.
    Nash AS, McAteer H, Schofield J, Penzer R, Gilbert AK. Psoriasis today:experiences of healthcare and impact on quality of life in a major UK cohort. Prim Health Care Res Dev 2014; 5: 1–9.Google Scholar
  7. 7.
    Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005; 64: 65–73.CrossRefGoogle Scholar
  9. 9.
    Linder D, Sampogna F, Torreggiani A, et al. Psodisk, a new visual method for assessing the burden of psoriasis on patients. J Eur Acad Dermatol Venereol 2012; 26: 1163–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Otero ME, Van Geel MJ, Hendriks JC, Van De Kerkhof PC, Seyger MM, De Jong EM. A pilot study on the Psoriasis Area and Severity Index (PASI) for small areas:presentation and implications of the Low PASI score. J Dermatolog Treat 2015; 26: 314–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Iglewicz B, Hoaglin D. How to detect and handle outliers. In:Mykytka EF. The ASQC Basic References in Quality Control:Statistical Techniques. Milwaukee:ASQC Quality Press, 1993: 16.Google Scholar
  12. 12.
    Darjani A, Heidarzadeh A, Golchai J, et al. Quality of life in psoriatic patients:a study using the short form–36. Int J Prev Med 2014; 5: 1146–52.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Armstrong AW, Harskamp CT, Schupp CW. Psoriasis and sexual behavior in men:examination of the National Health and Nutrition Examination Survey (NHANES) in the United States. J Sex Med 2014; 11: 394–400.CrossRefPubMedGoogle Scholar
  14. 14.
    Armstrong AW, Follansbee MR, Harskamp CT, Schupp CW. Psoriasis and sexual behavior in U.S. women:an epidemiologic analysis using the National Health and Nutrition Examination Survey (NHANES). J Sex Med 2013; 10: 326–32.CrossRefPubMedGoogle Scholar
  15. 15.
    Sampogna F, Linder D, Romano GV, Gualberti G, Merolla R, di Luzio Paparatti U. Results of the validation study of the Psodisk instrument, and determination of the cut–off scores for varying degrees of impairment. J Eur Acad Dermatol Venereol 2015; 29: 725–31.CrossRefPubMedGoogle Scholar

Copyright information

© John Libbey Eurotext 2018

Authors and Affiliations

  • Emanuele Cozzani
    • 1
  • Dennis Linder
    • 2
  • Martina Burlando
    • 1
  • Fabio Gallo
    • 3
  • Francesca Sampogna
    • 4
  • Marco Bruzzone
    • 5
  • Carlotta Tacchino
    • 1
  • Francesco Drago
    • 1
  • Aurora Parodi
    • 1
  1. 1.Section of DermatologyUniversity of Genoa, Di.S.Sal., San Martino Policlinic HospitalGenoaItaly
  2. 2.Unit of Epidemiology and BiostatisticsUniversity of OsloOsloNorway
  3. 3.Section of BiostatisticsUniversity of Genoa, Di.S.Sal., San Martino Policlinic HospitalGenoaItaly
  4. 4.Clinical Epidemiology UnitIDIRomeItaly
  5. 5.Biostatistics Unit, Clinical Epidemiology UnitUniversity of GenoaIRCCS San Martino-ISTItaly

Personalised recommendations